Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      GoHealth Reports Third Quarter 2021 Results

      Reaffirms Full-Year Guidance

      GoHealth, Inc. (PRNewsfoto/GoHealth, Inc.)

      News provided by

      GoHealth, Inc.

      Nov 09, 2021, 16:05 ET

      Share this article

      Share this article


      CHICAGO, Nov. 9, 2021 /PRNewswire/ -- GoHealth, Inc. (NASDAQ: GOCO), a leading health insurance marketplace and Medicare-focused digital health company, announced financial results for the three and nine months ended September 30, 2021.

      • Third quarter 2021 net revenue of $211.7 million increased 30% compared to the prior year period. YTD 2021 net revenue of $612.8 million increased 42% compared to the prior year period.
      • Third quarter 2021 Medicare—Internal revenue of $158.6 million increased 19% compared to the prior year period. YTD 2021 Medicare—Internal revenue of $476.4 million increased 51% compared to the prior year period.
      • Third quarter 2021 Medicare Advantage ("MA") Approved Submissions of 193,107 increased 100% compared to the prior year period. YTD 2021 MA Approved Submissions of 516,983 increased 67% compared to the prior year period.
      • Third quarter 2021 MA LTV Per Approved Submission of $926 decreased 6% compared to the prior year period. YTD 2021 MA LTV Per Approved Submission of $957 increased 5% compared to the prior year period.
      • Third quarter 2021 net loss of $55.4 million compared to a net loss of $206.5 million in the prior year period; Adjusted EBITDA1 of negative $14.1 million decreased 136% compared to the prior year period due to the 2021 strategic investments in agent capacity, marketplace technology, branding and the Encompass Platform. YTD 2021 net loss was $101.9 million compared to a net loss of $230.3 million in the prior year period; Adjusted EBITDA1 of $32.3 million decreased 68% compared to the prior year period.
      • The Company reaffirmed its full-year 2021 outlook, and expects total net revenue of $1,200 - $1,300 million (+37% to +48%) powered by commission net revenue of $1,000 - $1,100 million (+49% to +64%). The Company also reaffirms its Adjusted EBITDA1 outlook of $300 - $330 million (+11% to +22%).

      Clint Jones, co-founder and CEO said, "During the third quarter, we delivered revenue growth of 30%, while also exceeding our agent hiring goals in preparation for a successful Annual Enrollment Period. We are excited about our ability to grow our membership base during AEP and deliver the trusted healthcare advice seniors need to navigate the increasingly complex Medicare market. This increase in our agent force will enable us to better serve more seniors during this year's AEP, grow our membership base and realize the potential of this enormous market opportunity. As a result of our agent hiring and momentum in our Encompass Platform, we are reaffirming our full-year 2021 guidance."

      Third Quarter 2021 Highlights2

      • Total company revenue grew 30% to $211.7 million, net of a $6.7 million negative revenue adjustment relating to revenue estimates from prior periods
      • Medicare—Internal net revenue increased 19% to $158.6 million
      • LTV Per carrier Approved MA Submission decreased 6% to $926
      • Adjusted EBITDA1 decreased 136% to negative $14.1 million
        • Investment in customer care and enrollment grew to $87.8 million, an increase of 112% excluding non-cash share-based compensation expense relating to the accelerated vesting of performance-vesting units in connection with the IPO in prior year results, which primarily represents the costs to hire and onboard agents in advance of the Annual Enrollment Period ("AEP")
          • Agent counts grew well ahead of the 50% target as the Company prepares for the AEP and fiscal 2022
        • Total cost of revenue, marketing and advertising expense grew 28%, roughly in line with sales growth

      YTD 2021 Highlights2

      • Total company revenue grew 42% to $612.8 million
      • Medicare—Internal net revenue increased 51% to $476.4 million
      • LTV Per carrier Approved MA Submission increased 5% to $957
      • Adjusted EBITDA1 decreased 68% to $32.3 million
        • Investment in customer care and enrollment grew to $196.8 million, an increase of 110% excluding non-cash share-based compensation expense relating to the accelerated vesting of performance-vesting units in connection with the IPO in prior year results, which primarily represents the costs to hire and onboard agents in advance of the AEP
        • Total cost of revenue, marketing and advertising expense grew 44%, roughly in line with sales growth

      2021 Financial Outlook

      The trajectory of the U.S. economy remains challenging to predict, particularly given the continued uncertainty associated with the pace of recovery from the COVID-19 pandemic. The Company is reaffirming its financial outlook for the fiscal year ending December 31, 2021 based on current market conditions and expectations:

      • Full-year 2021 net revenue of $1,200 - $1,300 million, representing year-over-year growth of 37% - 48%
        • Full-year 2021 commission revenue of $1,000 - $1,100 million, representing year-over-year growth of 49% - 64%, fueled by the Company's continued investment in its Medicare business, including GoHealth's Encompass Platform
      • Full-year 2021 Adjusted EBITDA1 of $300 - $330 million, representing year-over-year growth of 11% - 22%

      Conference Call Details

      The Company will host a conference call today, Tuesday, November 9, 2021 at 5:00 p.m. (ET) to discuss its financial results.  A live audio webcast and a supplemental presentation will be available online at https://investors.gohealth.com. The conference call can also be accessed by dialing 1-833-519-1310 for U.S. participants, or 1-914-800-3876 for international participants, and referencing participant code 2553159. A replay of the call will be available for 30 days via webcast for on-demand listening shortly after the completion of the call, at the same web link.

      About GoHealth, Inc.:

      As a leading health insurance marketplace and Medicare-focused digital health company, GoHealth's mission is to improve access to healthcare in America. Enrolling in a health insurance plan can be confusing for customers, and the seemingly small differences between plans can lead to significant out-of-pocket costs or lack of access to critical medicines and even providers. GoHealth combines cutting-edge technology, data science and deep industry expertise to match customers with the healthcare policy and carrier that is right for them. GoHealth has enrolled millions of people in Medicare plans and individual and family plans. For more information, visit https://www.gohealth.com.

      Investor Relations:
      [email protected]

      Media Relations:
      [email protected]


      (1)

      Adjusted EBITDA is a non-GAAP measure. For a definition of Adjusted EBITDA and a reconciliation to the most comparable GAAP measure, please see below.

      (2)

      Third quarter and YTD 2021 results compared to the comparable prior year period.

      Forward-Looking Statements

      This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Statements regarding the Company's future results of operations and financial position, business strategy and plans and objectives of management for future operations, including, among others, statements regarding expected financial performance and operational performance for the fiscal year 2021, including with respect to revenue and Adjusted EBITDA, the growth of our membership base, and our ability to realize the potential of our market opportunity are forward-looking statements. In some cases, you can identify forward-looking statements by terms, such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements. There are or will be important factors that could cause the Company's actual results to differ materially from those indicated in these forward-looking statements, including, but are not limited to, the following: the Company's ability to comply with the numerous, complex and frequently changing laws regulating the marketing and sale of Medicare plans; the potential for an adverse change in the Company's relationships with carriers, including a loss of a carrier relationship; failure to grow the Company's customer base or retain its existing customers; the time and cost of training agents are significant and can increase during a period of high attrition; carriers' ability to reduce commissions paid to the Company and adversely change their underwriting practices; significant consolidation in the healthcare industry which could adversely alter the Company's relationships with carriers; information technology systems failures or capacity constraints interrupting the Company's operations; factors that adversely impact the Company's estimate of LTV; the Company's dependence on agents to sell insurance plans; changes in the health insurance system and laws and regulation governing health insurance markets; the inability to effectively advertise the Company's products; and our ability to successfully implement our business plan during a global economic downturn caused by the COVID-19 pandemic.

      The foregoing factors should not be construed as exhaustive and should be read together with the other cautionary statements included in this press release, as well as the cautionary statements and other risk factors set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 and other SEC filings. If one or more events related to these or other risks or uncertainties materialize, or if the Company's underlying assumptions prove to be incorrect, actual results may differ materially from what the Company anticipates. Many of the important factors that will determine these results are beyond the Company's ability to control or predict. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, the Company does not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. New factors emerge from time-to-time, and it is not possible for us to predict which will arise. In addition, the Company cannot assess the impact of each factor on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

      Use of Non-GAAP Financial Measures and Key Performance Indicators

      In this press release, we use supplemental measures of our performance that are derived from our consolidated financial information, but which are not presented in our Consolidated Financial Statements prepared in accordance with Generally Accepted Accounting Principles ("GAAP"). These non-GAAP financial measures include net income (loss) before interest expense, income tax expense (benefit) and depreciation and amortization expense ("EBITDA"); Adjusted EBITDA and Adjusted EBITDA margin. Adjusted EBITDA is the primary financial performance measure used by management to evaluate its business and monitor its results of operations.

      Adjusted EBITDA represents, as applicable for the period, EBITDA as further adjusted for share-based compensation expense, accelerated vesting of certain equity awards, loss on extinguishment of debt, loss on sublease, non-recurring legal fees, change in fair value of contingent consideration liability, IPO transaction costs, and severance costs. Adjusted EBITDA margin represents Adjusted EBITDA divided by net revenues.

      We use non-GAAP financial measures to supplement financial information presented on a GAAP basis. We believe that excluding certain items from our GAAP results allows management to better understand our consolidated financial performance from period to period and better project our future consolidated financial performance as forecasts are developed at a level of detail different from that used to prepare GAAP-based financial measures. Moreover, we believe these non-GAAP financial measures provide our stakeholders with useful information to help them evaluate our operating results by facilitating an enhanced understanding of our operating performance and enabling them to make more meaningful period to period comparisons. There are limitations to the use of the non-GAAP financial measures presented in this press release. For example, our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

      The non-GAAP financial measures are not meant to be considered as indicators of performance in isolation from or as a substitute for net income (loss) prepared in accordance with GAAP, and should be read only in conjunction with financial information presented on a GAAP basis. Reconciliations of each of EBITDA and Adjusted EBITDA to its most directly comparable GAAP financial measure, net income (loss), are presented in the tables below in this press release. We encourage you to review the reconciliations in conjunction with the presentation of the non-GAAP financial measures for each of the periods presented. In future periods, we may exclude similar items, may incur income and expenses similar to these excluded items and include other expenses, costs and non-recurring items.

      Management has provided its outlook regarding Adjusted EBITDA, which is a non-GAAP financial measure and excludes certain charges. Reconciliations of Adjusted EBITDA to its most directly comparable GAAP financial measure, net income (loss), is presented in the table below in this press release.

      Glossary

      "Adjusted EBITDA" represents, as applicable for the period, EBITDA as further adjusted for share-based compensation expense, accelerated vesting of certain equity awards, loss on extinguishment of debt, loss on sublease, non-recurring legal fees, change in fair value of contingent consideration liability, IPO transaction costs, and severance costs.

      "Adjusted EBITDA Margin" refers to Adjusted EBITDA divided by net revenues.

      "Approved Submissions" refer to Submitted Policies approved by carriers for the identified product during the indicated period.

      "LTV Per Approved Submission" refers to the Lifetime Value of Commissions per Approved Submission, which we define as (i) aggregate commissions estimated to be collected over the estimated life of all commissionable Approved Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, carrier mix and expected policy persistency with applied constraints, excluding revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods, divided by (ii) the number of commissionable Approved Submissions for such period.

      "Revenue Per Submission" refers to the total net revenues per Submitted Policy, which we define as (i) total net revenue, excluding revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods, divided by (ii) the number of Submitted Policies for such period.

      "Submitted Policies" refer to completed applications that, with respect to each such application, the consumer has authorized us to submit to the carrier.

      The following tables set forth the components of our results of operations for the periods indicated (unaudited):

      (in thousands, except percentages and per share amounts)


      Three months ended Sep.
      30, 2021


      Three months ended Sep.
      30, 2020






      Dollars


      % of Net
      Revenues


      Dollars


      % of Net
      Revenues


      $ Change


      % Change

      Net revenues:













      Commission


      $

      174,948



      82.6

      %


      $

      101,390



      62.1

      %


      $

      73,558



      72.5

      %

      Enterprise


      36,786



      17.4

      %


      61,970



      37.9

      %


      (25,184)



      (40.6)

      %

      Net revenues


      211,734



      100.0

      %


      163,360



      100.0

      %


      48,374



      29.6

      %

      Operating expenses:













      Cost of revenue


      53,632



      25.3

      %


      25,827



      15.8

      %


      27,805



      107.7

      %

      Marketing and advertising


      59,511



      28.1

      %


      62,848



      38.5

      %


      (3,337)



      (5.3)

      %

      Customer care and enrollment


      87,813



      41.5

      %


      52,896



      32.4

      %


      34,917



      66.0

      %

      Technology


      11,651



      5.5

      %


      39,520



      24.2

      %


      (27,869)



      (70.5)

      %

      General and administrative


      24,232



      11.4

      %


      156,551



      95.8

      %


      (132,319)



      (84.5)

      %

      Amortization of intangible assets


      23,514



      11.1

      %


      23,514



      14.4

      %


      —



      —

      %

      Total operating expenses


      260,353



      123.0

      %


      361,156



      221.1

      %


      (100,803)



      (27.9)

      %

      Income (loss) from operations


      (48,619)



      (23.0)

      %


      (197,796)



      (121.1)

      %


      149,177



      (75.4)

      %

      Interest expense


      6,921



      3.3

      %


      8,636



      5.3

      %


      (1,715)



      (19.9)

      %

      Loss on extinguishment of debt


      —



      —

      %


      —



      —

      %


      —



      N/M

      Other (income) expense


      (30)



      —

      %


      2



      —

      %


      (32)



      N/M

      Income (loss) before income taxes


      (55,510)



      (26.2)

      %


      (206,434)



      (126.4)

      %


      150,924



      (73.1)

      %

      Income tax expense (benefit)


      (79)



      —

      %


      62



      —

      %


      (141)



      N/M

      Net income (loss)


      $

      (55,431)



      (26.2)

      %


      $

      (206,496)



      (126.4)

      %


      $

      151,065



      (73.2)

      %

      Net income (loss) attributable to noncontrolling interests


      (35,248)



      (16.6)

      %


      (150,076)



      (91.9)

      %


      114,828



      N/M

      Net income (loss) attributable to GoHealth, Inc.


      $

      (20,183)



      (9.5)

      %


      $

      (56,420)



      (34.5)

      %


      $

      36,237



      (64.2)

      %

      Net income (loss) per share:













      Net income (loss) per share of common stock — basic and diluted (1)


      $

      (0.18)





      $

      (0.65)








      Weighted-average shares of Class A common stock outstanding — basic and diluted


      113,938





      84,183








      Non-GAAP financial measures:













      EBITDA


      $

      (22,519)





      $

      (173,021)








      Adjusted EBITDA


      $

      (14,068)





      $

      39,284








      Adjusted EBITDA margin


      (6.6)

      %




      24.0

      %













      NM = Not meaningful

      (1)

      Net loss per share of Class A common stock—basic and diluted is the same for both the three and nine months ended September 30, 2020 as both periods are based on the post-IPO net loss from July 17, 2020 to September 30, 2020.

      (in thousands, except percentages and per share amounts)


      Nine months ended Sep.
      30, 2021


      Nine months ended Sep.
      30, 2020






      Dollars


      % of Net
      Revenues


      Dollars


      % of Net
      Revenues


      $ Change


      % Change

      Net revenues:













      Commission


      $

      496,437



      81.0

      %


      $

      310,506



      72.0

      %


      $

      185,931



      59.9

      %

      Enterprise


      116,378



      19.0

      %


      120,921



      28.0

      %


      (4,543)



      (3.8)

      %

      Net revenues


      612,815



      100.0

      %


      431,427



      100.0

      %


      181,388



      42.0

      %

      Operating expenses:













      Cost of revenue


      139,449



      22.8

      %


      104,520



      24.2

      %


      34,929



      33.4

      %

      Marketing and advertising


      169,730



      27.7

      %


      110,556



      25.6

      %


      59,174



      53.5

      %

      Customer care and enrollment


      196,834



      32.1

      %


      105,267



      24.4

      %


      91,567



      87.0

      %

      Technology


      33,251



      5.4

      %


      49,818



      11.5

      %


      (16,567)



      (33.3)

      %

      General and administrative


      69,176



      11.3

      %


      177,400



      41.1

      %


      (108,224)



      (61.0)

      %

      Change in fair value of contingent consideration liability


      —



      —

      %


      19,700



      4.6

      %


      (19,700)



      N/M

      Amortization of intangible assets


      70,543



      11.5

      %


      70,543



      16.4

      %


      —



      —

      %

      Total operating expenses


      678,983



      110.8

      %


      637,804



      147.8

      %


      41,179



      6.5

      %

      Income (loss) from operations


      (66,168)



      (10.8)

      %


      (206,377)



      (47.8)

      %


      140,209



      (67.9)

      %

      Interest expense


      23,886



      3.9

      %


      24,378



      5.7

      %


      (492)



      (2.0)

      %

      Loss on extinguishment of debt


      11,935



      1.9

      %


      —



      —

      %


      11,935



      N/M

      Other (income) expense


      27



      —

      %


      (494)



      (0.1)

      %


      521



      (105.5)

      %

      Income (loss) before income taxes


      (102,016)



      (16.6)

      %


      (230,261)



      (53.4)

      %


      128,245



      (55.7)

      %

      Income tax expense (benefit)


      (142)



      —

      %


      38



      —

      %


      (180)



      N/M

      Net income (loss)


      $

      (101,874)



      (16.6)

      %


      $

      (230,299)



      (53.4)

      %


      $

      128,425



      (55.8)

      %

      Net loss attributable to noncontrolling interests


      (67,612)



      (11.0)

      %


      (150,076)



      (34.8)

      %


      $

      82,464



      (54.9)

      %

      Net loss attributable to GoHealth, Inc.


      $

      (34,262)



      (5.6)

      %


      $

      (80,223)



      (18.6)

      %


      $

      45,961



      (57.3)

      %

      Net income (loss) per share:













      Net income (loss) per share of common stock — basic and diluted (1)


      $

      (0.33)





      $

      (0.65)








      Weighted-average shares of Class A common stock outstanding — basic and diluted


      102,939





      84,183








      Non-GAAP financial measures:













      EBITDA


      $

      (955)





      $

      (132,441)








      Adjusted EBITDA


      $

      32,322





      $

      101,141








      Adjusted EBITDA margin


      5.3

      %




      23.4

      %













      NM = Not meaningful

      (1)

      Net loss per share of Class A common stock—basic and diluted is the same for both the three and nine months ended September 30, 2020 as both periods are based on the post-IPO net loss from July 17, 2020 to September 30, 2020.


      The following tables set forth the reconciliations of GAAP net income (loss) to EBITDA and Adjusted EBITDA for the periods indicated (unaudited):

      (in thousands)


      Three months
      ended Sep.
      30, 2021


      Three months
      ended Sep.
      30, 2020

      Net revenues


      $

      211,734



      $

      163,360


      Net income (loss)


      (55,431)



      (206,496)


      Interest expense


      6,921



      8,636


      Income tax expense (benefit)


      (79)



      62


      Depreciation and amortization expense


      26,070



      24,777


      EBITDA


      (22,519)



      (173,021)


      Share-based compensation expense (1)


      7,389



      2,770


      Accelerated vesting of certain equity awards (2)


      —



      209,300


      Loss on sublease (3)


      1,062



      —


      IPO transaction costs (4)


      —



      235


      Adjusted EBITDA


      $

      (14,068)



      $

      39,284


      Adjusted EBITDA margin


      (6.6)

      %


      24.0

      %







      (1)

      Represents non-cash share-based compensation expense relating to equity awards.

      (2)

      Represents non-cash share-based compensation expense relating to the accelerated vesting of performance-vesting units in connection with the IPO for the three months ended September 30, 2020.

      (3)

      Represents the loss related to a sublease agreement entered into during the three months ended September 30, 2021.

      (4)

      Represents legal, accounting, consulting, and other indirect costs associated with the Company's IPO.

      (in thousands)


      Nine months
      ended Sep.
      30, 2021


      Nine months
      ended Sep.
      30, 2020

      Net revenues


      $

      612,815



      $

      431,427


      Net income (loss)


      (101,874)



      (230,299)


      Interest expense


      23,886



      24,378


      Income tax expense (benefit)


      (142)



      38


      Depreciation and amortization expense


      77,175



      73,442


      EBITDA


      (955)



      (132,441)


      Loss on extinguishment of debt (1)


      11,935



      —


      Share-based compensation expense (2)


      20,100



      3,846


      Accelerated vesting of certain equity awards (3)


      —



      209,300


      Loss on sublease (4)


      1,062



      —


      Legal fees (5)


      180



      —


      Change in fair value of contingent consideration liability (6)


      —



      19,700


      IPO transaction costs (7)


      —



      659


      Severance costs (8)


      —



      77


      Adjusted EBITDA


      $

      32,322



      $

      101,141


      Adjusted EBITDA margin


      5.3

      %


      23.4

      %







      (1)

      Represents the loss on debt extinguishment related to the Initial Term Loan Facility.

      (2)

      Represents non-cash share-based compensation expense relating to equity awards.

      (3)

      Represents non-cash share-based compensation expense relating to the accelerated vesting of performance-vesting units in connection with the IPO for the nine months ended September 30, 2020.

      (4)

      Represents the loss related to a sublease agreement entered into during the nine months ended September 30, 2021.

      (5)

      Represents non-recurring legal fees unrelated to our core operations.

      (6)

      Represents the change in fair value of the contingent consideration liability due to the predecessor owners of the Company arising from the Centerbridge Acquisition.

      (7)

      Represents legal, accounting, consulting, and other indirect costs associated with the Company's IPO.

      (8)

      Represents costs associated with the termination of employment.


      The following table summarizes share-based compensation expense by operating function for the periods indicated (unaudited):

      (in thousands)


      Three
      months
      ended Sep.
      30, 2021


      Three
      months
      ended Sep.
      30, 2020


      Nine
      months
      ended Sep.
      30, 2021


      Nine
      months
      ended Sep.
      30, 2020

      Marketing and advertising


      $

      698



      $

      24,709



      $

      1,462



      $

      24,829


      Customer care and enrollment


      957



      11,993



      2,796



      12,050


      Technology


      910



      32,748



      2,791



      32,907


      General and administrative


      4,824



      142,620



      13,051



      143,360


      Total share-based compensation expense


      $

      7,389



      $

      212,070



      $

      20,100



      $

      213,146



      The following table sets forth our balance sheets for the periods indicated (unaudited):

      (in thousands, except per share amounts)


      Sep. 30, 2021


      Dec. 31, 2020

      Assets





      Current assets:





      Cash and cash equivalents


      $

      85,221



      $

      144,234


      Accounts receivable, net of allowance for doubtful accounts of $634 in 2021 and $787 in 2020


      8,578



      14,211


      Receivable from NVX Holdings, Inc.


      —



      3,395


      Commissions receivable - current


      133,422



      188,128


      Prepaid expense and other current assets


      29,291



      41,854


      Total current assets


      256,512



      391,822


      Commissions receivable - non-current


      837,958



      622,270


      Other long-term assets


      3,988



      2,072


      Property, equipment, and capitalized software, net


      27,424



      17,353


      Intangible assets, net


      618,183



      688,726


      Goodwill


      386,553



      386,553


      Total assets


      $

      2,130,618



      $

      2,108,796


      Liabilities and Stockholders' Equity





      Current liabilities:





      Accounts payable


      $

      24,297



      $

      8,733


      Accrued liabilities


      32,737



      26,926


      Commissions payable - current


      60,303



      78,478


      Deferred revenue


      561



      736


      Current portion of long-term debt


      4,270



      4,170


      Other current liabilities


      10,764



      8,328


      Total current liabilities


      132,932



      127,371


      Non-current liabilities:





      Commissions payable - non-current


      237,005



      182,596


      Long-term debt, net of current portion


      439,216



      396,400


      Other non-current liabilities


      3,676



      3,274


      Total non-current liabilities


      679,897



      582,270


      Stockholders' equity:





      Class A common stock – $0.0001 par value; 1,100,000 shares authorized; 114,713 and 84,196 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively.


      11



      8


      Class B common stock – $0.0001 par value; 588,002 and 619,004 shares authorized; 205,995 and 236,997 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively.


      21



      24


      Preferred stock – $0.0001 par value; 20,000 shares authorized; no shares issued and outstanding at September 30, 2021 and December 31, 2020.


      —



      —


      Additional paid-in capital


      550,455



      399,169


      Accumulated other comprehensive income (loss)


      (4)



      17


      Accumulated deficit


      (53,064)



      (18,802)


      Total stockholders' equity attributable to GoHealth, Inc.


      497,419



      380,416


      Non-controlling interests


      820,370



      1,018,739


      Total stockholders' equity


      1,317,789



      1,399,155


      Total liabilities and stockholders' equity


      $

      2,130,618



      $

      2,108,796


      The following table sets forth our statements of cash flows for the periods indicated (unaudited):

      (in thousands)


      Nine months
      ended Sep.
      30, 2021


      Nine months
      ended Sep.
      30, 2020

      Operating Activities





      Net income (loss)


      $

      (101,874)



      $

      (230,299)


      Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:





      Share-based compensation


      20,100



      213,146


      Depreciation and amortization


      6,632



      2,899


      Amortization of intangible assets


      70,543



      70,543


      Amortization of debt discount and issuance costs


      1,696



      1,744


      Change in fair value of contingent consideration


      —



      19,700


      Loss on extinguishment of debt


      11,935



      —


      Loss on sublease


      1,062



      —


      Other non-cash items


      (708)



      (1,100)


      Changes in assets and liabilities, net of acquisition:





      Accounts receivable


      6,173



      14,860


      Commissions receivable


      (160,982)



      (117,888)


      Prepaid expenses and other assets


      10,471



      (10,884)


      Accounts payable


      18,298



      (4,402)


      Accrued liabilities


      5,693



      (1,793)


      Deferred revenue


      (175)



      40,188


      Commissions payable


      36,233



      27,983


      Other liabilities


      2,484



      4,138


      Net cash provided by (used in) operating activities


      (72,419)



      28,835


      Investing Activities





      Purchases of property, equipment and software


      (19,269)



      (12,023)


      Net cash used in investing activities


      (19,269)



      (12,023)


      Financing Activities





      Proceeds from issuance of Class A common stock sold in initial public offering, net of offering costs


      —



      852,407


      Payment of partial consideration of the Blocker Merger


      —



      (96,165)


      Purchase of LLC Interests


      —



      (508,320)


      Settlement of Senior Preferred Earnout Units


      —



      (100,000)


      Proceeds received upon issuance of common units


      —



      10,000


      Borrowings under term loans


      335,000



      117,000


      Payments of term loans


      (297,903)



      (2,835)


      Call premium paid for debt extinguishment


      (5,910)



      —


      Debt issuance cost payments


      (1,608)



      (6,291)


      Principal payments under capital lease obligations


      (231)



      (218)


      Cash received on advancement to NVX Holdings, Inc.


      3,395



      —


      Net cash provided by financing activities


      32,743



      265,578


      Effect of exchange rate changes on cash and cash equivalents


      (68)



      (68)


      Increase in cash and cash equivalents


      (59,013)



      282,322


      Cash and cash equivalents at beginning of period


      144,234



      12,276


      Cash and cash equivalents at end of period


      $

      85,221



      $

      294,598


      Supplemental Disclosure of Cash Flow Information





      Non-cash investing and financing activities:





      Purchases of property, equipment and software included in accounts payable


      $

      2,734



      $

      1,104


      Issuance of senior preferred earnout units to settle contingent consideration liability


      $

      —



      $

      100,000


      Issuance of common A and B units to settle contingent consideration liability


      $

      —



      $

      100,000


      Issuance of Class A and Class B common stock in connection with Reorganization Transactions


      $

      —



      $

      30


      Settlement of contingent consideration liability


      $

      —



      $

      62,400


      The following tables set forth operating segment results for the periods indicated (unaudited):

      (in thousands, except percentages)


      Three months ended Sep.
      30, 2021


      Three months ended Sep.
      30, 2020






      Dollars


      % of Net
      Revenues


      Dollars


      % of Net
      Revenues


      $ Change


      % Change

      Net revenues:













      Medicare - Internal


      $

      158,605



      74.9

      %


      $

      133,723



      82.0

      %


      $

      24,882



      18.6

      %

      Medicare - External


      46,237



      21.8

      %


      20,252



      12.4

      %


      25,985



      128.3

      %

      IFP and Other - Internal


      5,742



      2.7

      %


      6,147



      3.8

      %


      (405)



      (6.6)

      %

      IFP and Other - External


      1,150



      0.5

      %


      3,238



      2.0

      %


      (2,088)



      (64.5)

      %

      Net revenues


      211,734



      100.0

      %


      163,360



      100.0

      %


      48,374



      29.6

      %

      Segment profit (loss):













      Medicare - Internal


      (4,126)



      (1.9)

      %


      49,464



      30.3

      %


      (53,590)



      (108.3)

      %

      Medicare - External


      1,866



      0.9

      %


      720



      0.4

      %


      1,146



      N/M

      IFP and Other - Internal


      2,186



      1.0

      %


      (245)



      (0.1)

      %


      2,431



      N/M

      IFP and Other - External


      (330)



      (0.2)

      %


      147



      0.1

      %


      (477)



      (324.5)

      %

      Segment profit (loss)


      (404)



      (0.2)

      %


      50,086



      30.7

      %


      (50,490)



      (100.8)

      %

      Corporate expense


      24,701



      11.7

      %


      224,368



      137.3

      %


      (199,667)



      (89.0)

      %

      Amortization of intangible assets


      23,514



      11.1

      %


      23,514



      14.4

      %


      —



      —

      %

      Interest expense


      6,921



      3.3

      %


      8,636



      5.3

      %


      (1,715)



      (19.9)

      %

      Other (income) expense


      (30)



      —

      %


      2



      —

      %


      (32)



      N/M

      Income (loss) before income taxes


      $

      (55,510)



      (26.2)

      %


      $

      (206,434)



      (126.4)

      %


      $

      150,924



      (73.1)

      %







      NM = Not meaningful



      Nine months ended Sep.
      30, 2021


      Nine months ended Sep.
      30, 2020





      (in thousands, except percentages)


      Dollars


      % of Net
      Revenues


      Dollars


      % of Net
      Revenues


      $ Change


      % Change

      Net revenues:













      Medicare - Internal


      $

      476,391



      77.7

      %


      $

      316,211



      73.3

      %


      $

      160,180



      50.7

      %

      Medicare - External


      117,116



      19.1

      %


      77,305



      17.9

      %


      39,811



      51.5

      %

      IFP and Other - Internal


      13,505



      2.2

      %


      21,798



      5.1

      %


      (8,293)



      (38.0)

      %

      IFP and Other - External


      5,803



      0.9

      %


      16,113



      3.7

      %


      (10,310)



      (64.0)

      %

      Net revenues


      612,815



      100.0

      %


      431,427



      100.0

      %


      181,388



      42.0

      %

      Segment profit (loss):













      Medicare - Internal


      73,574



      12.0

      %


      123,946



      28.7

      %


      (50,372)



      (40.6)

      %

      Medicare - External


      (453)



      (0.1)

      %


      892



      0.2

      %


      (1,345)



      N/M

      IFP and Other - Internal


      657



      0.1

      %


      181



      —

      %


      476



      N/M

      IFP and Other - External


      (227)



      —

      %


      789



      0.2

      %


      (1,016)



      (128.8)

      %

      Segment profit (loss)


      73,551



      12.0

      %


      125,808



      29.2

      %


      (52,257)



      (41.5)

      %

      Corporate expense


      69,176



      11.3

      %


      241,942



      56.1

      %


      (172,766)



      (71.4)

      %

      Change in fair value of contingent consideration liability


      —



      —

      %


      19,700



      4.6

      %


      (19,700)



      N/M

      Amortization of intangible assets


      70,543



      11.5

      %


      70,543



      16.4

      %


      —



      —

      %

      Loss on extinguishment of debt


      11,935



      1.9

      %


      —



      —

      %


      11,935



      N/M

      Interest expense


      23,886



      3.9

      %


      24,378



      5.7

      %


      (492)



      (2.0)

      %

      Other (income) expense


      27



      —

      %


      (494)



      (0.1)

      %


      521



      (105.5)

      %

      Income (loss) before income taxes


      $

      (102,016)



      (16.6)

      %


      $

      (230,261)



      (53.4)

      %


      $

      128,245



      (55.7)

      %







      NM = Not meaningful


      The following table presents the number of Submitted Policies by product for the Medicare segments for the three and nine months ended September 30, 2021 and 2020, for those submissions that are commissionable (compensated through commissions received from carriers):

      Medicare - Total Commissionable Submitted Policies


      Three
      months
      ended Sep.
      30, 2021


      Three
      months
      ended Sep.
      30, 2020


      Nine
      months
      ended Sep.
      30, 2021


      Nine
      months
      ended Sep.
      30, 2020

      Medicare Advantage


      149,680


      97,675


      475,717


      314,088

      Medicare Supplement


      648


      1,245


      2,774


      6,164

      Prescription Drug Plans


      1,923


      2,006


      6,890


      6,437

      Total Medicare


      152,251


      100,926


      485,381


      326,689

      The following tables present the number of Approved Submissions by product relating to commissionable policies for the Medicare segments for three and nine months ended September 30, 2021 and 2020. Only commissionable policies are used to calculate LTV.

      Medicare - Internal Commissionable Approved Submissions


      Three
      months
      ended Sep.
      30, 2021


      Three
      months
      ended Sep.
      30, 2020


      Nine
      months
      ended Sep.
      30, 2021


      Nine
      months
      ended Sep.
      30, 2020

      Medicare Advantage


      145,619


      77,186


      395,804


      228,612

      Medicare Supplement


      183


      315


      702


      1,602

      Prescription Drug Plans


      2,208


      1,574


      6,525


      5,319

      Total Medicare


      148,010


      79,075


      403,031


      235,533



      Medicare - External Commissionable Approved Submissions


      Three
      months
      ended Sep.
      30, 2021


      Three
      months
      ended Sep.
      30, 2020


      Nine
      months
      ended Sep.
      30, 2021


      Nine
      months
      ended Sep.
      30, 2020

      Medicare Advantage


      47,488


      19,390


      121,179


      80,656

      Medicare Supplement


      427


      844


      1,823


      4,035

      Prescription Drug Plans


      191


      352


      716


      1,206

      Total Medicare


      48,106


      20,586


      123,718


      85,897

      The following table presents the LTV per Approved Submission by product for the Medicare segments for the three and nine months ended September 30, 2021 and 2020:

      LTV per Approved Submission


      Three
      months
      ended Sep.
      30, 2021


      Three
      months
      ended Sep.
      30, 2020


      Nine
      months
      ended Sep.
      30, 2021


      Nine
      months
      ended Sep.
      30, 2020

      Medicare Advantage


      $

      926


      $

      987


      $

      957


      $

      913

      Medicare Supplement


      $

      874


      $

      934


      $

      834


      $

      929

      Prescription Drug Plans


      $

      215


      $

      215


      $

      215


      $

      216

      The following table presents the number of Submitted Policies by product for the Medicare segments for the three and nine months ended September 30, 2021 and 2020, for those submissions that are non-commissionable (compensated via hourly fees and enrollment fees) and do not result in commission revenue:

      Medicare - Total Non-Commissionable Submitted Policies


      Three
      months
      ended Sep.
      30, 2021


      Three
      months
      ended Sep.
      30, 2020


      Nine
      months
      ended Sep.
      30, 2021


      Nine
      months
      ended Sep.
      30, 2020

      Medicare Advantage


      1,532


      6,472


      10,703


      20,806

      Medicare Supplement


      1,327


      1,716


      5,019


      5,262

      Prescription Drug Plans


      542


      1,034


      2,218


      2,787

      Total Medicare


      3,401


      9,222


      17,940


      28,855

      The following table presents a reconciliation from net income to non-GAAP Adjusted EBITDA guidance for the twelve months ended December 31, 2021:



      Twelve months ended

      Dec. 31, 2021



      Guidance Range

      (in thousands)


      Low


      High

      Net revenues


      $

      1,200,000



      $

      1,300,000


      Net income


      126,603



      156,603


      Interest expense


      30,000



      30,000


      Income tax expense


      220



      220


      Depreciation and amortization expense


      102,000



      102,000


      EBITDA


      258,823



      288,823


      Loss on extinguishment of debt (1)


      11,935



      11,935


      Share-based compensation expense (2)


      28,000



      28,000


      Loss on sublease (3)


      1,062



      1,062


      Legal fees (4)


      180



      180


      Adjusted EBITDA


      $

      300,000



      $

      330,000


      Adjusted EBITDA margin


      25

      %


      25

      %







      (1)

      Represents the loss on debt extinguishment related to the Term Loan Facility.

      (2)

      Represents non-cash share-based compensation expense relating to equity awards.

      (3)

      Represents the loss related to a sublease agreement.

      (4)

      Represents non-recurring legal fees unrelated to our core operations.

      SOURCE GoHealth, Inc.

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.